2.Etiology and management of postoperative gastrointestinal bleeding after orthotopic liver transplantation.
Yi MA ; Xiao-Shun HE ; Xiao-Feng ZHU ; Guo-Dong WANG ; Dong-Ping WANG ; An-Bin HU ; Wei-Qiang JU ; Lin-Wei WU ; Qiang TAI
Chinese Journal of Gastrointestinal Surgery 2010;13(1):26-28
OBJECTIVETo investigate the causes and treatment of postoperative gastrointestinal bleeding after orthotopic liver transplantation (OLT).
METHODSClinical data of 776 patients after OLT between January 2000 and December 2006 were analyzed retrospectively.The experiences in diagnosis and treatment of postoperative gastrointestinal bleeding after OLT were reviewed.
RESULTSGastrointestinal bleeding occurred in 18 patients (2.3%) after OLT, among whom 8 (44.5%) were from peptic ulcer, 3 (16.7%) from gastric and esophageal varices, 3 (16.7%) from gastroduodenitis, 3 (16.7%) from hemobilia, and 1 (5.6%) had diverticular bleeding in the jejunum. These 18 patients with gastrointestinal bleeding were managed with conservative treatment, endoscopic treatment, radiological interventional embolism,or exploratory laparotomy. Five patients died of gastrointestinal bleeding and the gastrointestinal bleeding-related mortality rate was 27.8%. After a mean follow up of 3.5 years, only 1 patient died of recurrence of hepatic cellular carcinoma while others survived disease-free.
CONCLUSIONSGastrointestinal bleeding may occur from different sites after OLT and the mortality is high. Prompt identification of the source of bleeding and correct management are required to improve the prognosis.
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Female ; Gastrointestinal Hemorrhage ; etiology ; prevention & control ; Humans ; Liver Transplantation ; adverse effects ; Male ; Middle Aged ; Postoperative Hemorrhage ; prevention & control ; Retrospective Studies ; Young Adult
3.Effect of partial splenic embolization in prevention of gastroesophageal variceal rebleeding.
Chang-hui YU ; Chun-chi HUANG ; Zhen-shu ZHANG
Journal of Southern Medical University 2010;30(5):1138-1140
OBJECTIVETo evaluate the effect of partial splenic embolization (PSE) in prevention of gastroesophageal variceal rebleeding.
METHODSSixty-two patients with recent gastroesophageal variceal bleeding were treated by PSE with Seldinger technique. All the patients were followed-up for 12 months. The data including peripheral blood cell count, liver function, plasma prothrombin time (PT), portal vein diameter, and appearance of gastroesophageal varices under gastroscopy were collected before and after embolization for statistical analysis.
RESULTSFive days after the operation, the numbers of leucocytes and platelets were significantly increased (P<0.05), and PT was significantly shortened (P<0.05). All the patients showed a good response after PSE with reduced internal diameter of the portal vein and blood flow (P<0.05). Gastroesophageal varices were relieved in all the patients. Rebleeding occurred in 11 patients during the follow-up.
CONCLUSIONPSE can be effective in preventing gastroesophageal variceal rebleeding.
Adult ; Aged ; Embolization, Therapeutic ; methods ; Esophageal and Gastric Varices ; etiology ; surgery ; Female ; Follow-Up Studies ; Gastrointestinal Hemorrhage ; etiology ; prevention & control ; Gastroscopy ; Humans ; Male ; Middle Aged ; Splenic Artery
4.Influence of endoscopic variceal ligation on liver function and risk factors of rebleeding.
Fen WANG ; Guangkui BU ; Shourong SHEN ; Wuliang TANG ; Canxia XU
Journal of Central South University(Medical Sciences) 2013;38(5):521-525
OBJECTIVE:
To investigate the influence of endoscopic variceal ligation (EVL) on liver function and analyze the risk factors of rebleeding after EVL.
METHODS:
A total of 137 cirrhotic patients with esophageal varices who received EVL were retrospectively analyzed, and divided into group A, B, and C according to the Child-Pugh scores of liver function. We compared the liver function 1 week preoperatively and postoperatively. The patients were further divided into a rebleeding group and a non-rebleeding group after the EVL, and risk factors about rebleeding were analyzed.
RESULTS:
There was no significant difference on ALT, AST, T-Bil, and D-Bil either preoperatively or postoperatively in group A, B, and C (P>0.05). Thirteen patients (9.49%) rebled after the EVL. The course of disease, liver function, prothrombin time, and mass ascites were the risk factors of rebleeding.
CONCLUSION
EVL has no obvious effect on liver function, and the course of disease, liver function, prothrombin time and mass ascites are risk factors of rebleeding after EVL.
Adult
;
Endoscopy
;
methods
;
Esophageal and Gastric Varices
;
etiology
;
surgery
;
Female
;
Gastrointestinal Hemorrhage
;
etiology
;
prevention & control
;
surgery
;
Humans
;
Ligation
;
methods
;
Liver
;
physiopathology
;
Liver Cirrhosis
;
complications
;
etiology
;
physiopathology
;
Logistic Models
;
Male
;
Middle Aged
;
Recurrence
;
Risk Factors
;
Secondary Prevention
5.Prevention of Esophageal Variceal Bleeding.
The Korean Journal of Gastroenterology 2010;56(3):155-167
Esophageal varices(EV) are present in 40% and 60% of Child-Pugh A and C patients, respectively when cirrhosis is diagnosed. EV bleeding is a life-threatening complication of liver cirrhosis with a high probability of recurrence. Treatment to prevent first EV bleeding or rebleeding is mandatory. In small EV with high risk of bleeding, nonselective beta-blockers should be used for the prevention of first variceal bleeding. For medium to large EV, nonselective beta-blockers or endoscopic variceal ligation (EVL) may be recommended to high risk varices. But, nonselective beta-blockers are the first treatment option to non-high risk varices and EVL is an alternative when nonselective beta-blockers are contraindicated or not tolerated. For the prevention of rebleeding, a combination of nonselective beta-blockers and EVL may be the best option. A great improvement in the prevention of variceal bleeding has emerged over the last years. However, further therapeutic options that combine higher efficacy, better tolerance and fewer side effects are needed.
Adrenergic beta-Antagonists/therapeutic use
;
Esophageal and Gastric Varices/drug therapy/*prevention & control
;
Gastrointestinal Hemorrhage/*etiology
;
Humans
;
Ligation
;
Portasystemic Shunt, Transjugular Intrahepatic
;
Sclerotherapy
6.Application of timolol in preventing variceal hemorrhage in patients with portal hypertension.
Zhong-hua SHANG ; Hai-yun CHEN ; Hong-lin DONG
Acta Academiae Medicinae Sinicae 2010;32(5):553-556
OBJECTIVETo determine the effectiveness of timolol in preventing first variceal hemorrhage in portal hypertensive patients with esophageal varices.
METHODSA total of 42 cirrhotic patients with esophageal varices were enrolled in this study and received timolol or band ligation therapy randomly,with 21 patients in each group. The diameters of portal vein (PV), superior mesenteric vein (SMV), and splenic vein (SPV) as well as the portal venous flow and the splenic venous flow were measured. The first esophageal variceal bleeding of the two groups was recorded.
RESULTSThe diameters of PV, SMV, and SPV as well as the flow of PV and SPV showed no significant difference before and after treatment in band ligation group (P>0.05). In timolol group,however,the diameter of portal vein significantly decreased after treatment [(14.11±2.96) mm vs. (12.15±1.61)mm, P<0.05], and the average blood flow of portal vein also significantly decreased after treatment [(1277.33±495.19) ml/min vs. (719.17±245.16)ml/min, P<0.05]. Both timolol and band ligation effectively prevented esophageal variceal bleeding, and the risk of first esophageal variceal bleeding in these two groups were not significantly different (15% vs. 10%, P<0.05).
CONCLUSIONSTimolol is safe and effective in preventing the first variceal bleeding in portal hypertensive patients with esophageal varices.
Adult ; Aged ; Female ; Gastrointestinal Hemorrhage ; etiology ; prevention & control ; Humans ; Hypertension, Portal ; complications ; Ligation ; Male ; Middle Aged ; Timolol ; therapeutic use ; Young Adult
8.Management of portal hypertensive gastropathy and other bleeding.
Clinical and Molecular Hepatology 2014;20(1):1-5
A major cause of cirrhosis related morbidity and mortality is the development of variceal bleeding, a direct consequence of portal hypertension. Less common causes of gastrointestinal bleeding are peptic ulcers, malignancy, angiodysplasia, etc. Upper gastrointestinal bleeding has been classified according to the presence of a variceal or non-variceal bleeding. Although non-variceal gastrointestinal bleeding is not common in cirrhotic patients, gastroduodenal ulcers may develop as often as non-cirrhotic patients. Ulcers in cirrhotic patients may be more severe and less frequently associated with chronic intake of non-steroidal anti-inflammatory drugs, and may require more frequently endoscopic treatment. Portal hypertensive gastropathy (PHG) refers to changes in the mucosa of the stomach in patients with portal hypertension. Patients with portal hypertension may experience bleeding from the stomach, and pharmacologic or radiologic interventional procedure may be useful in preventing re-bleeding from PHG. Gastric antral vascular ectasia (GAVE) seems to be different disease entity from PHG, and endoscopic ablation can be the first-line treatment.
Gastric Antral Vascular Ectasia/complications
;
Gastric Mucosa/pathology
;
Gastrointestinal Hemorrhage/*etiology
;
Humans
;
Hypertension, Portal/*complications/prevention & control
;
Liver Cirrhosis/complications
;
Peptic Ulcer/complications
9.A randomized placebo-controlled multicentre study of Fuzhenghuayu capsule for prevention of oesophageal variceal bleeding in patients with liver cirrhosis.
Dinghong XIAO ; Jie GU ; Hong CAI ; Qin ZHANG ; Dongying XUE ; Changqing ZHAO ; Lieming XU
Chinese Journal of Hepatology 2014;22(8):594-599
OBJECTIVETo evaluate the efficacy of Fuzhenghuayu capsule for the prevention of oesophageal variceal bleeding in patients with liver cirrhosis.
METHODSA multicentre randomized placebo-controlled trial was conducted. A total of 181 liver cirrhosis patients were enrolled in the study and randomly assigned to different groups according to the level of oesophageal variceal bleeding. Patients with light oesophageal varices received Fuzhenghuayu capsule or a placebo. Patients with medium to heavy oesophageal varices received either Fuzhenghuayu capsule alone, Fuzhenghuayu capsule plus propranolol, or propranolol plus a placebo. Patients with a history of oesophageal variceal bleeding received either Fuzhenghuayu capsule plus propranolol, propranolol alone, or a placebo. For all patients, the treatment lasted 2 years. The primary end point of the study was oesophageal variceal bleeding. The secondary end points were liver cancer, death by any cause, and liver transplantation. Risk of bleeding and survival were statistically assessed.
RESULTSThe median follow-up time was 50 months. The patients with small oesophageal varices who were treated with Fuzhenghuayu capsule showed a significantly higher cumulative probability of bleeding than their counterparts treated with the placebo (3.4% vs. 23.7%, x² = 4.829, P =0.028). The patients with medium to heavy oesophageal varices and no history of oesophageal variceal bleeding who were treated with Fuzhenghuayu capsule plus propranolol showed a remarkably higher cumulative probability of bleeding than their counterparts treated with propranolol alone (15.2% vs. 43.6%, x² =6.166, P =0.013). There were no significant differences between the patients treated with Fuzhenghuayu capsule alone and those treated with propranolol alone (P =0.147) or the patients treated with Fuzhenghuayu capsule plus propranolol and those treated with Fuzhenghuayu capsule alone (P =0.147). The patients with history of oesophageal variceal bleeding who were treated with Fuzhenghuayu capsule showed significantly higher cumulative probability of bleeding and median time of bleeding than their counterparts treated with propranolol alone (44.0% vs. 24.2% and 40.00 ± 17.92 months vs. 7.00 ± 2.35 months; x² = 4.433, P =0.035). There were no significant differences in the cumulative probability of liver cancer and survival among all of the groups.
CONCLUSIONFuzhenghuayu capsule can decrease the cumulative probability of bleeding in cirrhotic patients with light oesophageal varices. For cirrhosis patients with a history of oesophageal variceal bleeding, the combination of Fuzhenghuayu capsule plus propranolol can decrease the cumulative probability of bleeding with median or heavy varices.
Adult ; Double-Blind Method ; Drugs, Chinese Herbal ; therapeutic use ; Esophageal and Gastric Varices ; etiology ; prevention & control ; Female ; Gastrointestinal Hemorrhage ; etiology ; prevention & control ; Humans ; Liver Cirrhosis ; complications ; drug therapy ; Male ; Middle Aged ; Phytotherapy ; Prospective Studies ; Treatment Outcome
10.Therapeutic and prevention strategies of gastroesophageal varices and variceal hemorrhage in cirrhosis.
Chinese Journal of Hepatology 2009;17(4):252-253
Adrenergic beta-Antagonists
;
therapeutic use
;
Antiviral Agents
;
therapeutic use
;
Esophageal and Gastric Varices
;
etiology
;
prevention & control
;
Gastrointestinal Hemorrhage
;
diagnosis
;
etiology
;
prevention & control
;
Gastroscopy
;
Hemostasis, Endoscopic
;
methods
;
Hemostatic Techniques
;
Hemostatics
;
therapeutic use
;
Humans
;
Hypertension, Portal
;
complications
;
Liver Cirrhosis
;
complications